User login
Key clinical point: The use vs. nonuse of cimetropium bromide as premedication is associated with higher gastric neoplasm detection rate during esophagogastroduodenoscopy (EGD) screening.
Major finding: In 41,670 matched participants, the gastric neoplasm detection rate was significantly higher in the cimetropium bromide vs. control group (0.30% vs. 0.19%; P = .02). Cimetropium bromide use vs. nonuse was associated with a significantly higher combined detection rate of dysplasia and early gastric cancer (0.27% vs. 0.17%; P = .02). Cimetropium bromide was associated with higher odds for the detection of gastric neoplasms (odds ratio 1.42; P = .03).
Study details: This article reports a propensity score-matched retrospective cohort study of 67,683 participants who received EGD screening with cimetropium bromide (41.8%) or without (control group; 58.2%).
Disclosures: This study was supported by the Ministry of Education, Science, and Technology, Korea; and Myongji Hospital. The authors declared no competing interests.
Source: Kim SY et al. Assessment of cimetropium bromide use for the detection of gastric neoplasms during esophagogastroduodenoscopy. JAMA Netw Open. 2022;5(3):e223827 (Mar 23). Doi: 10.1001/jamanetworkopen.2022.3827
Key clinical point: The use vs. nonuse of cimetropium bromide as premedication is associated with higher gastric neoplasm detection rate during esophagogastroduodenoscopy (EGD) screening.
Major finding: In 41,670 matched participants, the gastric neoplasm detection rate was significantly higher in the cimetropium bromide vs. control group (0.30% vs. 0.19%; P = .02). Cimetropium bromide use vs. nonuse was associated with a significantly higher combined detection rate of dysplasia and early gastric cancer (0.27% vs. 0.17%; P = .02). Cimetropium bromide was associated with higher odds for the detection of gastric neoplasms (odds ratio 1.42; P = .03).
Study details: This article reports a propensity score-matched retrospective cohort study of 67,683 participants who received EGD screening with cimetropium bromide (41.8%) or without (control group; 58.2%).
Disclosures: This study was supported by the Ministry of Education, Science, and Technology, Korea; and Myongji Hospital. The authors declared no competing interests.
Source: Kim SY et al. Assessment of cimetropium bromide use for the detection of gastric neoplasms during esophagogastroduodenoscopy. JAMA Netw Open. 2022;5(3):e223827 (Mar 23). Doi: 10.1001/jamanetworkopen.2022.3827
Key clinical point: The use vs. nonuse of cimetropium bromide as premedication is associated with higher gastric neoplasm detection rate during esophagogastroduodenoscopy (EGD) screening.
Major finding: In 41,670 matched participants, the gastric neoplasm detection rate was significantly higher in the cimetropium bromide vs. control group (0.30% vs. 0.19%; P = .02). Cimetropium bromide use vs. nonuse was associated with a significantly higher combined detection rate of dysplasia and early gastric cancer (0.27% vs. 0.17%; P = .02). Cimetropium bromide was associated with higher odds for the detection of gastric neoplasms (odds ratio 1.42; P = .03).
Study details: This article reports a propensity score-matched retrospective cohort study of 67,683 participants who received EGD screening with cimetropium bromide (41.8%) or without (control group; 58.2%).
Disclosures: This study was supported by the Ministry of Education, Science, and Technology, Korea; and Myongji Hospital. The authors declared no competing interests.
Source: Kim SY et al. Assessment of cimetropium bromide use for the detection of gastric neoplasms during esophagogastroduodenoscopy. JAMA Netw Open. 2022;5(3):e223827 (Mar 23). Doi: 10.1001/jamanetworkopen.2022.3827